CIK 0001880438
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
AN2 Therapeutics, Inc.
Sign in to watch- Ticker
- ANTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 820606654
- Phone
- +1 650-331-9090
- Business address
- 1300 EL CAMINO REAL, SUITE 100, MENLO PARK, CA, 94025
- Open-market buys, last 90 days
- $11,602
- in 1 filing
- Open-market sales, last 90 days
- $117,428
- in 4 filings, $104K under 10b5-1 plans
Net −$105,826. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-03-29 | Readnour Robin Shane Director | Purchase | +82,618 | $15.00 | $1.2M | 487,592 |
| 2022-03-29 | Readnour Robin Shane Director | Conversion · Series A Convertible Preferred Stock | −285,156 | 0 | ||
| 2022-03-29 | Readnour Robin Shane Director | Conversion · Series A Convertible Preferred Stock | −333,135 | 0 | ||
| 2022-03-29 | Readnour Robin Shane Director | Conversion · Series B Convertible Preferred Stock | −61,491 | 0 | ||
| 2022-03-29 | Readnour Robin Shane Director | Conversion · Series B Convertible Preferred Stock | −71,839 | 0 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion | +1,651,636 | 1,651,636 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion | +312,415 | 312,415 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion | +392,433 | 2,044,069 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion | +74,230 | 386,645 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Purchase | +166,666 | $15.00 | $2.5M | 2,210,735 |
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −1,651,636 | 0 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion · Series A Convertible Preferred Stock | −312,415 | 0 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −392,433 | 0 | ||
| 2022-03-29 | Adjuvant Global Health Technology Fund, L.P. 10% owner | Conversion · Series B Convertible Preferred Stock | −74,230 | 0 | ||
| 2022-03-29 | Easom Eric Chief Executive Officer | Conversion | +4,907 | 4,907 | ||
| 2022-03-29 | Easom Eric Chief Executive Officer | Conversion · Series A Convertible Preferred Stock | −4,907 | 0 | ||
| 2022-03-29 | Aziz Kabeer Director | Conversion | +1,651,636 | 1,651,636 | ||
| 2022-03-29 | Aziz Kabeer Director | Conversion | +312,415 | 312,415 | ||
| 2022-03-29 | Aziz Kabeer Director | Conversion | +392,433 | 2,044,069 | ||
| 2022-03-29 | Aziz Kabeer Director | Conversion | +74,230 | 386,645 |
Page 19 of 20 · 385 trades